GeneDx Holdings reported strong financial results for the fourth quarter and full year 2024, surpassing market expectations. The company achieved Q4 revenue of $95.64 million, exceeding the $82.23 million estimate, and adjusted net income of $16.8 million. Adjusted gross margins for Q4 expanded to 70%. For the full year, GeneDx raised its 2025 revenue guidance to a range of $350 million to $360 million, above the consensus estimate of $338.77 million. The company anticipates adjusted gross margins of 65%-67% for 2025 and expects profitability in all quarters of the year. GeneDx's stock surged 35% to $103 following the announcement, with a 21.5% pre-market gain. The company was the top midcap performer in 2024, with a 2,700% increase in stock value.